Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19

Journal of the American College of Cardiology(2021)10.1016/j.jacc.2021.02.035Source: DataRank Database

Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19 is a research paper published in Journal of the American College of Cardiology (2021). On theSindex it has a DataRank of 0.780. It has been cited 180 times.

N/A

0.780DataRank · unranked

Scored on demand from live citation data

180 citations

Download PDF

Cite:

Linked data & code

nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 10.67)OA: bronzeTopics (33)Linked Datasets (10)DataCite Reuse (10)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (0/2)

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.780

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (27)

Parham Sadeghipour ORCID,Hessam Kakavand ORCID,Maryam Aghakouchakzadeh ORCID,Elaheh Kordzadeh-Kermani,Benjamin W. Van Tassell

Live enrichment

PubMed:33741176 PMC:PMC7963001 OpenAlex:https://openalex.org/W3138214175

National Institute for Health Research (NIHR)

Grant: NIHR201320

National Institute for Health Research (NIHR)

Grant: NF-SI-0616-10010

NCATS NIH HHS

Grant: UL1 TR001863

FWCI

10.67

Citation Percentile

1.0%

Citation Trend

2021

2022

2023

2024

2025

2026

bronzeLicense: http://www.elsevier.com/open-access/userlicense/1.0/

journalhttps://www.sciencedirect.com/science/article/pii/S0735109721004587/pdf

publisherhttps://www.sciencedirect.com/science/article/pii/S0735109721004587/pdf

publisherhttps://api.elsevier.com/content/article/PII:S0735109721004587?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0735109721004587?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.jacc.2021.02.035

Fields of Study

COVID-19 Clinical Research StudiesLong-Term Effects of COVID-19Venous Thromboembolism Diagnosis and ManagementCOVID-19Fibrinolytic AgentsHumansRandomized Controlled Trials as TopicThromboembolismCOVID-19 Drug Treatment

MeSH Terms

COVID-19COVID-19 Drug TreatmentFibrinolytic AgentsHumansThromboembolismRandomized Controlled Trials as Topic

Keywords

MedicineAntithromboticRandomized controlled trialCoronavirus disease 2019 (COVID-19)Intensive care medicineClinical trialSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Thrombosis2019-20 coronavirus outbreakPerspective (graphical)DiseaseInternal medicinePathologyInfectious disease (medical specialty)AnticoagulantantiplateletRctCovid-19

Sustainable Development Goals

SDG 0: Good health and well-being

Additional file 1 of Efficacy and safety of direct-acting oral anticoagulants compared to vitamin K antagonists in COVID-19 outpatients with cardiometabolic diseases

10.6084/m9.figshare.16570909.v1figshare

Additional file 1 of Efficacy and safety of direct-acting oral anticoagulants compared to vitamin K antagonists in COVID-19 outpatients with cardiometabolic diseases

10.6084/m9.figshare.16570909figshare

Additional file 1 of Intermediate dose enoxaparin in hospitalized patients with moderate-severe COVID-19: a pilot phase II single-arm study, INHIXACOVID19

10.6084/m9.figshare.26631046.v1figshare

Additional file 1 of Intermediate dose enoxaparin in hospitalized patients with moderate-severe COVID-19: a pilot phase II single-arm study, INHIXACOVID19

10.6084/m9.figshare.26631046figshare

Additional file 2 of Intermediate dose enoxaparin in hospitalized patients with moderate-severe COVID-19: a pilot phase II single-arm study, INHIXACOVID19

10.6084/m9.figshare.26631049.v1figshare

Additional file 2 of Intermediate dose enoxaparin in hospitalized patients with moderate-severe COVID-19: a pilot phase II single-arm study, INHIXACOVID19

10.6084/m9.figshare.26631049figshare

Additional file 4 of Intermediate dose enoxaparin in hospitalized patients with moderate-severe COVID-19: a pilot phase II single-arm study, INHIXACOVID19

10.6084/m9.figshare.26631055.v1figshare

Additional file 4 of Intermediate dose enoxaparin in hospitalized patients with moderate-severe COVID-19: a pilot phase II single-arm study, INHIXACOVID19

10.6084/m9.figshare.26631055figshare

Additional file 3 of Intermediate dose enoxaparin in hospitalized patients with moderate-severe COVID-19: a pilot phase II single-arm study, INHIXACOVID19

10.6084/m9.figshare.26631052.v1figshare

Additional file 3 of Intermediate dose enoxaparin in hospitalized patients with moderate-severe COVID-19: a pilot phase II single-arm study, INHIXACOVID19

10.6084/m9.figshare.26631052figshare